In a recent ruling, Japanese pharmaceutical giant Daiichi Sankyo Ltd. emerged victorious in an arbitration case against U.S. biotech firm Seagen concerning a patent dispute over cancer drug technology. The pharmaceutical firm was awarded close to $46 million in fees and costs. The decision followed the arbitrator’s judgment that Seagen had breached the six-year statute of limitations period by failing to file its infringement claims within the prescribed time.
The dispute originated from the allegation of Seagen on infringement of its cancer drug technology. According to the claims, Sankyo, one of the global leaders in the pharmaceutical industry, violated patent rights related to this technology. However, the arbitration panel found merit in Sankyo’s defence, that Seagen did not meet the timeline set by the statute of limitations for filing such claims. As a result, Sankyo not only succeeded in defending the allegations but was also compensated for the ostensibly unwarranted legal proceeding.
This recent settlement is significant given the highly competitive nature of the pharmaceutical and biotech industries, where patent protection and enforcement play crucial roles. The outcome may have potential implications on future patent disputes, setting precedent for timeliness in filing infringement claims.
For more detailed coverage of this development, we suggest you read the complete report on Law360.